The first study (ALA in Diabetic Neuropathy Study) enrolled 328 patients with symptomatic peripheral neuropathy and non-insulin-dependent diabetes mellitus who were randomized to receive an intravenous infusion of ALA at three different doses (1200 mg, 600 mg, or 100 mg/day) or a placebo for a period of 3 weeks
Clinically Tested Ingredients
- Dihexa / Semax / Selank is a cGMP Aerosol research spray designed for laboratory investigations involving HGF pathway research, neuroplasticity-associated mechanisms, peptide signaling, stress-response biology, cognitive pathway models, neuroendocrine regulation, and central nervous system communication
J.JamesS
Wear comfortable clothing with easy sleeve access for IV placement
On top of these benefits, Lipo-C injections are extremely safe and low risk